Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5)
Annals of Internal Medicine · 2023-11 · 176 (11) · 1476-1485
DOI: 10.7326/m23-1288 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Annals of Internal Medicine, 2023-11. Verfasst von Harpreet S Bajaj und 8 weiteren Autor:innen. Beteiligte Einrichtung: LMC Diabetes and Endocrinology, Brampton, Ontario, Canada (H.S.B.). Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia, Mobile Applications. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Inadequate dose titration and poor adherence to basal insulin can lead to suboptimal glycemic control in persons with type 2 diabetes (T2D). Once-weekly insulin icodec (icodec) is a basal insulin analogue that is in development and is aimed at reducing treatment burden. OBJECTIVE: To compare the effectiveness and safety of icodec titrated with a dosing guide app (icodec with app) versus once-daily basal insulin analogues (OD analogues) dosed per standard practice. DESIGN: 52-week, randomized, open-label, parallel-group, phase 3a trial with real-world elements. (ClinicalTrials.gov: NCT04760626). SETTING: 176 sites in 7 countries. PARTICIPANTS: 1085 insulin-naive adults with T2D. INTERVENTION: Icodec with app or OD analogue (insulin degludec, insulin glargine U100, or insulin glargine U300). MEASUREMENTS: The primary outcome was change in glycated hemoglobin (HbA1c) level from baseline to week 52. Secondary outcomes included patient-reported outcomes (Treatment Related Impact Measure for Diabetes [TRIM-D] compliance domain score and change in Diabetes Treatment Satisfaction Questionnaire [DTSQ] total treatment satisfaction score). RESULTS: The estimated mean change in HbA1c level from baseline to week 52 was greater with icodec with app than with OD analogues, with noninferiority (P < 0.001) and superiority (P = 0.009) confirmed in prespecified hierarchical testing (estimated treatment difference [ETD], -0.38 percentage points [95% CI, -0.66 to -0.09 percentage points]). At week 52, patient-reported outcomes were more favorable with icodec with app than with OD analogues (ETDs, 3.04 [CI, 1.28 to 4.81] for TRIM-D and 0.78 [CI, 0.10 to 1.47] for DTSQ). Rates of clinically significant or severe hypoglycemia were low and similar with both treatments. LIMITATION: Inability to differentiate the effects of icodec and the dosing guide app. CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates. PRIMARY FUNDING SOURCE: Novo Nordisk A/S.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- LMC Diabetes and Endocrinology, Brampton, Ontario, Canada (H.S.B.).
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany (J.A.).
- Diabetes Research Centre, University of Leicester, and Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, United Kingdom (M.D.).
- Novo Nordisk A/S, Søborg, Denmark (A.M.D., M.F., A.G.).
- Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey (D.G.Y.).
- Division of Endocrinology, Department of Internal Medicine and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas (I.L.).
ORCID-Profile: Harpreet S Bajaj, Jens Aberle, Melanie Davies, Anders Meller Donatsky, Dilek G Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce Bode
Zitieren
APA
Bajaj, H. S., Aberle, J., Davies, M., Donatsky, A. M., Frederiksen, M., Yavuz, D. G., Gowda, A., Lingvay, I., & Bode, B. (2023). Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5). Annals of Internal Medicine, 176(11), 1476-1485. https://doi.org/10.7326/m23-1288
Vancouver
Bajaj HS, Aberle J, Davies M, Donatsky AM, Frederiksen M, Yavuz DG, et al. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5). Annals of Internal Medicine. 2023;176(11):1476-1485. doi:10.7326/m23-1288
BibTeX
@article{Bajaj2023,
author = {Bajaj, Harpreet S and Aberle, Jens and Davies, Melanie and Donatsky, Anders Meller and Frederiksen, Marie and Yavuz, Dilek G and Gowda, Amoolya and Lingvay, Ildiko and Bode, Bruce},
title = {Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5)},
journal = {Annals of Internal Medicine},
year = {2023},
volume = {176},
number = {11},
pages = {1476--1485},
doi = {10.7326/m23-1288}
}
EUVIMED